Agios Pharma (8AP) Stock Statistics & Valuation Metrics

Agios Pharma has a market cap or net worth of CHF1.94B. The enterprise value is $1.29K.

Agios Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.

The current PE Ratio of Agios Pharma is ―. Agios Pharma’s PEG ratio is 0.02.

In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.

In the last 12 months, operating cash flow was -380.41M and capital expenditures -4.32M, giving a free cash flow of -384.73M billion.

Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Agios Pharma upcoming earnings date is Jul 30, 2026, TBA (Confirmed).

Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.22%

In the past 12 months, Agios Pharma has paid -1.02M in taxes.

Agios Pharma EV to EBITDA ratio is -3.80, with an EV/FCF ratio of -4.11.

Agios Pharma has CHF737.04M in cash and marketable securities with CHF35.74M in debt, giving a net cash position of CHF701.29M billion.

Gross margin is 82.07%, with operating margin of -873.87%, and net profit margin of -764.01%.

The average price target for Agios Pharma is CHF31.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy